WASHINGTON, DC, March 26, 2026 (EZ Newswire) -- The Scientific Association of Botanical Education and Research today commended Johns Hopkins University for its leadership in advancing rigorous, evidence-based clinician education through its continuing medical education (CME) program, "Introduction to Psychedelic Medicine and Psilocybin: Understanding the Science and Clinical Practices." Education like this plays a critical role in improving patient outcomes by equipping clinicians with the knowledge to make informed, safe, and effective treatment decisions.
Hosted by the Johns Hopkins Center for Psychedelics and Consciousness Research, this accredited CME course is designed for physicians, advanced practice providers, psychologists, and other healthcare professionals seeking a foundational understanding of psychedelic-assisted therapies. The program provides a structured, science-forward overview of psilocybin and related compounds, including pharmacology, mechanisms of action, therapeutic potential, and current clinical trial data.
The course also addresses key elements of clinical practice, including patient screening, preparation, dosing sessions, and integration, as well as essential safety considerations such as contraindications, adverse event monitoring, and the importance of set and setting. In addition, the curriculum explores the evolving legal and regulatory landscape, equipping clinicians to navigate a rapidly changing field with clarity and responsibility.
“This type of continuing education is critical as interest in psychedelic therapies accelerates,” said Dr. Mary Hardy, MD, member of SABER’s Scientific Steering Committee. “Programs like this ensure that clinicians are not only informed by emerging data, but also grounded in the principles of patient safety, ethical care, and scientific rigor.”
The one-day accredited program offers continuing education credits and is delivered through expert-led lectures from leading researchers and clinicians in the field. Participants gain practical insights into how psychedelic therapies are being studied today and what responsible clinical integration may look like in the future.
SABER emphasized that initiatives like this play an essential role in bridging the gap between research and real-world application. As psychedelic medicine continues to evolve, clinician education will be a key determinant of both patient outcomes and public trust.